PKM and metabolic dysfunction-associated steatotic liver disease: As shown in Fig. 7A, PKM2 was greatly expressed in the livers, especially in hepatic macrophages of NAFLD mice, whereas celastrol treatment effectively decreased PKM2 expression in hepatic macrophages.